| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Vandetanib | FIMM | pan-cancer | AAC | 0.2 | 0.2 |
| mRNA | selumetinib:MK-2206 (8:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.04 | 0.2 |
| mRNA | ML239 | CTRPv2 | pan-cancer | AAC | 0.041 | 0.3 |
| mRNA | MGCD-265 | CTRPv2 | pan-cancer | AAC | -0.039 | 0.3 |
| mRNA | I-BET-762 | GDSC1000 | pan-cancer | AAC | 0.031 | 0.3 |
| mRNA | myriocin | CTRPv2 | pan-cancer | AAC | -0.092 | 0.3 |
| mRNA | Cytarabine | CTRPv2 | pan-cancer | AAC | 0.032 | 0.3 |
| mRNA | TGX221 | GDSC1000 | pan-cancer | AAC | -0.054 | 0.3 |
| mRNA | RG-108 | CTRPv2 | pan-cancer | AAC | 0.041 | 0.3 |
| mRNA | ABT-737 | CTRPv2 | pan-cancer | AAC | 0.041 | 0.3 |